Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.47 |
| ▸ | CHRNG | P07510 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.47 |
| ▸ | CHRND | Q07001 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928358 | 0.91 | ITGB3 (0.50) | CHRNA1CHRNGCHRNB1CHRNDACE | |
| SCHEMBL4121793 | 0.91 | ITGB3 (0.50) | CHRNA1CHRNGCHRNB1CHRNDACE | |
| SCHEMBL29542801 | 0.91 | ITGB3 (0.50) | CHRNA1CHRNGCHRNB1CHRNDACE | |
| SCHEMBL3652453 | 0.86 | POLB (0.62) | POLBTSHRBIRC2ACEACE2 | |
| SCHEMBL4385669 | 0.86 | POLB (0.62) | POLBTSHRBIRC2ACEACE2 | |
| SCHEMBL6826832 | 0.85 | NPSR1 (0.53) | NLRP3POLBTSHRALDH1A1CNR2 | |
| SCHEMBL1721283 | 0.85 | NPSR1 (0.53) | NLRP3POLBTSHRALDH1A1CNR2 | |
| SCHEMBL8008631 | 0.85 | NPSR1 (0.53) | NLRP3POLBTSHRALDH1A1CNR2 | |
| SCHEMBL14638337 | 0.84 | CTSK (0.48) | CHRNA1CHRNGCHRNB1CHRNDACE | |
| SCHEMBL14623159 | 0.84 | ALDH1A1 (0.61) | NLRP3TSHRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004670-B1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO KG (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-2004670-A1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AiCuris GmbH & Co. KG (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007118693-A1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | DLST, VIP, HAMP | NLRP3 356/4885POLB 1754/4885CHRNA1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.